Science Applications Intl’s Return On Capital Employed Overview

According to Benzinga Pro, during Q1, Science Applications Intl (NYSE:SAIC) earned $98.00 million, a 30.67% increase from the…

According to Benzinga Pro, during Q1, Science Applications Intl (NYSE:SAIC) earned $98.00 million, a 30.67% increase from the preceding quarter. Science Applications Intl also posted a total of $2.03 billion in sales, a 3.05% increase since Q4. Science Applications Intl earned $75.00 million, and sales totaled $1.97 billion in Q4.

Why Is ROCE Significant?

Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Science Applications Intl posted an ROCE of 0.06%.

It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company’s recent performance, but does not account for factors that could affect earnings and sales in the near future.

ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Science Applications Intl is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For Science Applications Intl, the positive return on capital employed ratio of 0.06% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

Upcoming Earnings Estimate

Science Applications Intl reported Q1 earnings per share at $2.14/share, which beat analyst predictions of $1.77/share.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Orthopedic Devices Maker Treace Medical Concepts’ Gloomy Forecast Cast Concerns Over Long-Term Viability

Treace Medical Concepts reports Q1 EPS loss of $(0.30), sales hit $51.11 million, up 21%. Surge in procedure kits sold due to expanded surgeon base and product mix shift. FY24 sales guidance adjusted to $201M-$211M. Analysts downgrade, citing competitive challenges.

TMCI

Read More

Earnings Outlook For Turning Point Brands

Turning Point Brands (NYSE:TPB) is set to give its latest quarterly earnings report on Wednesday, 2022-10-26. Here's what investors need to know before the announcement. Analysts estimate that Turning Point Brands will report an earnings per share (EPS) of $0.61.

TPB